Prospective study of regular aspirin use and the risk of breast cancer

Journal of the National Cancer Institute

Volumn 88, Issue 14, 1996, Pages 988-993

  Egan, Kathleen M ^a,c   Stampfer, Meir J ^b   Giovannucci, Edward ^b   Rosner, Bernard A ^b   Colditz, Graham A ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; FEMALE; HUMAN; NORMAL HUMAN; RISK FACTOR;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ASPIRIN; BREAST NEOPLASMS; DRUG UTILIZATION; FEMALE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; RISK FACTORS;

EID: 0029998249     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.14.988     Document Type: Article

References (41)

1. Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987; 47:5340-6.
2. Pollard M, Luckert PH. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 1980;64: 1323-7.
3. Narisawa T, Sato M, Tani M, Kudo T, Takahashi T, Goto A. Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res 1981;41:1954-7.
4. Pollard M, Luckert PH. Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 1981;214:558-9.
5. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101: 635-9.
6. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
7. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989;157:175-9.
8. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83-7.
9. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991;115;952-4.
10. Gonzaga RA, Lima FR, Cameiro S, Maciel J, Amarante Junior M. Sulindac treatment for familial polyposis coli [letter]. Lancet 1985;1: 751.
11. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988;48:4399-404.
12. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer [see comment citations in Medline]. J Natl Cancer Inst 1991;83:355-8.
13. Peleg II, Maibach HT, Brown SH, Wilcox M. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer [see comment citations in Medline]. Arch Intern Med 1994;154:394-9.
14. Muscat JE, Stellman SE, Wynder EL. Nonsteroidal antiinflammatory drugs and colorectal cancer [see comment citations in Medline]. Cancer 1994;74:1847-54.
15. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study [see comment citations in Medline]. Epidemiology 1994;5: 138-46.
16. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer [see comment citations in Medline]. N Engl J Med 1991;325:1593-6.
17. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals [see comment citations in Medline]. Ann Intern Med 1994; 121:241-6.
18. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin use and the risk for colorectal cancer in women [see comment citations in Medline]. N Engl J Med 1995;333:609-14.
19. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993;72:1171-7.
20. Greenberg ER, Baron JA, Freeman DH Jr, Mandel JS, Haile R. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 1993;85:912-6.
21. Logan RF, Little J, Hawtin PG, Hardcastle JD. Effect of aspirin and non-steroidal antiinflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme [see comment citations in Medline]. Br Med J 1993;307:285-9.
22. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575-89.
23. Thompson HJ, Briggs S, Paranka NS, Piazza GA, Brendel K, Gross PH, et al. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst 1995;87:1259-60.
24. Mehta RG, Moon RC. Characterization of effective chemopreventive agents in mammary gland in vitro using an initiating-promotion protocol. Anticancer Res 1991;11:593-6.
25. Carter CA, Milholland RJ, Shea W, Ip MM. Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res 1983; 43:3559-62.
26. McCormick DL, Madigan MJ, Moon RC. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res 1985;45:1803-8.
27. McCormick DL, Wilson AM. Combination chemoprevention of rat mammary carcinogenesis by indomethacin and butylated hydroxytoluene. Cancer Res 1986;46:3907-11.
28. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis [see comment citations in Medline]. J Natl Cancer Inst 1993;85:307-11.
29. Laakso M, Mutru O, Isomaki H, Koota K. Cancer mortality in patients with rheumatoid arthritis. J Rheumatol 1988;15:1319-22.
30. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978;31:691-6.
31. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly [see comment citation in Medline]. Br Med J 1989;299:1247-50.
32. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer [see comment citation in Medline]. Cancer Res 1993;53:1322-7.
33. Harris RE, Namboodiri KK, Stellman SD, Wynder EL. Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med 1995;24:119-20.
34. Harris RE, Namboodiri K, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996;7:203-5.
35. Rosenberg L. Nonsteroidal anti-inflammatory drugs and cancer. Prev Med 1995;24:107-9.
36. Stampfer MJ, Willett MC, Speizer FE, Dysert DC, Lipnick R, Rosner B, et al. Test of the National Death Index. Am J Epidemiol 1984; 119:837-9.
37. Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Speizer FE, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women [see comment citations in Medline]. JAMA 1991; 266:521-7.
38. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-220.
39. Heath CW Jr, Thun MJ, Greenberg ER, Levin B, Marnett LJ. Nonsteroidal antiinflammatory drugs and human cancer. Report of an interdisciplinary research workshop. Cancer 1994;74: 2885-8.
40. Anti-arthritic medication usage: United States, 1991. Statistical Bulletin of the Metropolitan Insurance Company 1992;73:25-34.
41. Copeland KT, Checkoway H, McMichael AJ, Holbrook RH. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol 1977;105:488-95.